Bio-Rad Laboratories, Inc. BIO
374.68 USD -11.32 (-2.93%)
Nov 12, 2026, 1:13 PM EST
372.47 Day range 389.98
236.73 52-week range 396.23
- YTD
- +23.66%
- 1 year
- +14.48%
News
globenewswire.com BIO-key Enters Gaming / Hospitality Market with Contract from Major U.S. Casino Resort BIO-key entered gaming & hospitality market with contract from major U.S. casino resort to deploy PortalGuard® IAM platform and Identity-Bound Biometrics.
seekingalpha.com Bio-Rad Laboratories, Inc. (BIO) Presents at 2026 UBS Global Healthcare Conference Transcript Bio-Rad Laboratories, Inc. ( BIO ) 2026 UBS Global Healthcare Conference November 10, 2026 8:00 AM EST Company Participants Roop Lakkaraju - Executive VP & CFO Conference Call Participants Douglas…
globenewswire.com Dyadic Applied BioSolutions, BRIG BIO and Strive Nutrition Announce a Strategic Collaboration to Accelerate the Commercialization of Precision-Fermented Alpha-Lactalbumin for Premium Nutrition Markets in the U.S. Dyadic Applied BioSolutions, BRIG BIO and Strive Nutrition Announce a Strategic Collaboration to Accelerate the Commercialization of Precision-Fermented Al
zacks.com Why Bio-Rad (BIO) International Revenue Trends Deserve Your Attention Examine the evolution of Bio-Rad's (BIO) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
benzinga.com RBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $440 RBC Capital analyst Dan Leonard maintains Bio-Rad Laboratories (NYSE:BIO) with a Outperform and raises the price target from $390 to $440.
globenewswire.com Medicus Pharma to Present at BIO-Europe 2026 Medicus Chief Medical Officer will Highlight Company's Focus on Precision Oncology, Anchored by CD228V targeted ADC and Partner Ready Therapeutic Programs Medicus Chief Medical Officer will Highlight…
marketbeat.com What Bio-Rad Laboratories (BIO) Said on Its Q3 Earnings Call Bio-Rad Laboratories NYSE: BIO reported modest third-quarter revenue growth, its first currency-neutral increase of 2026, as gains in clinical diagnostics and digital PCR instruments helped offset…
benzinga.com Bio-Rad Laboratories Q3 2026 Earnings Call Transcript Bio-Rad Laboratories (NYSE:BIO) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…
benzinga.com Bio-Rad Laboratories Affirms FY2026 Sales Guidance of $2.506B-$2.596B vs $2.588B Est Bio-Rad Laboratories (NYSE:BIO) affirms FY2026 sales outlook from $2.506 billion-$2.596 billion to $2.506 billion-$2.596 billion vs $2.588 billion estimate.
benzinga.com Bio-Rad Laboratories Q3 Adj. EPS $2.65 Beats $2.23 Estimate, Sales $656.400M Beat $649.950M Estimate Bio-Rad Laboratories (NYSE:BIO) reported quarterly earnings of $2.65 per share which beat the analyst consensus estimate of $2.23 by 18.83 percent. This is a 17.26 percent increase over earnings of…
benzinga.com RBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $390 RBC Capital analyst Dan Leonard maintains Bio-Rad Laboratories (NYSE:BIO) with a Outperform and raises the price target from $370 to $390.
benzinga.com Citigroup Maintains Neutral on Bio-Rad Laboratories, Raises Price Target to $330 Citigroup analyst Daniel Grosslight maintains Bio-Rad Laboratories (NYSE:BIO) with a Neutral and raises the price target from $300 to $330.- benzinga.com RBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $370 RBC Capital analyst Dan Leonard maintains Bio-Rad Laboratories (NYSE:BIO) with a Outperform and raises the price target from $320 to $370.
- benzinga.com Wells Fargo Maintains Equal-Weight on Bio-Rad Laboratories, Raises Price Target to $330 Wells Fargo analyst Evan Stampler maintains Bio-Rad Laboratories (NYSE:BIO) with a Equal-Weight and raises the price target from $310 to $330.
- benzinga.com Bio-Rad Laboratories Lowers FY2026 Sales Guidance of $2.506B-$2.596B vs $2.567B Est Bio-Rad Laboratories (NYSE:BIO) lowers FY2026 sales outlook from $2.506 billion-$2.596 billion to $2.506 billion-$2.596 billion vs $2.567 billion estimate.
benzinga.com Bio-Rad Laboratories Q2 Adj. EPS $2.62 Beats $1.75 Estimate, Sales $651.000M Beat $623.989M Estimate Bio-Rad Laboratories (NYSE:BIO) reported quarterly earnings of $2.62 per share which beat the analyst consensus estimate of $1.75 by 49.71 percent. This is a 0.38 percent increase over earnings of…
benzinga.com Why Elliott Sees Hidden Billions Inside Bio-Rad Laboratories Elliott Management builds a stake in Bio-Rad (NYSE: BIO) to push for better performance, but family voting control could pose a hurdle.
benzinga.com Nasdaq 100 Drops Over 1%, Oil Tops $106 On Iran Impasse: Stock Market Today Nasdaq sinks 1.1% as AMAT, MU, ORCL and Vertiv crater on AI capex jitters, while WTI tops $106 and the 10-year yield hovers near 4.6% on stalled US-Iran talks.
benzinga.com Toyo Posts Upbeat Q1 Earnings, Joins Brady, Dominion Energy And Other Big Stocks Moving Higher On Monday TOYO shares rose 13.7% after beating earnings expectations. Other top gainers include JLHL, RAMP, HIVE, TE, AUTL, GENI, BRC, BIO, BL, RBLX, ZETA, and D.- benzinga.com 'Activist Elliott Builds Big Stake in Life-Science Tools Supplier Bio-Rad' - WSJ https://www.wsj.com/business/deals/activist-elliott-builds-big-stake-in-life-science-tools-supplier-bio-rad-c99b23fa
benzinga.com RBC Capital Reinstates Outperform on Bio-Rad Laboratories, Announces $320 Price Target RBC Capital analyst Dan Leonard reinstates Bio-Rad Laboratories (NYSE:BIO) with a Outperform and announces $320 price target.
benzinga.com Stock Market Today: Apple Earnings Power S&P 500, Nasdaq To Records; Trump Hits EU U.S. stocks hit fresh records as Apple's blowout Q2 powered Big Tech, while crude oil sank 3% on Hormuz news and Trump set 25% EU auto tariffs.- benzinga.com Wells Fargo Maintains Equal-Weight on Bio-Rad Laboratories, Lowers Price Target to $290 Wells Fargo analyst Brandon Couillard maintains Bio-Rad Laboratories (NYSE:BIO) with a Equal-Weight and lowers the price target from $320 to $290.
- benzinga.com Bio-Rad Laboratories Lowers FY2026 Sales Guidance from $2.596B-$2.622B to $2.506B-$2.596B vs $2.630B Est Bio-Rad Laboratories (NYSE:BIO) lowers FY2026 sales outlook from $2.596 billion-$2.622 billion to $2.506 billion-$2.596 billion vs $2.630 billion estimate.
benzinga.com Transcript: Bio-Rad Laboratories Q1 2026 Earnings Conference Call - benzinga.com Bio-Rad Laboratories Q1 Adj. EPS $1.89 Misses $1.98 Estimate, Sales $592.100M Beat $588.875M Estimate Bio-Rad Laboratories (NYSE:BIO) reported quarterly earnings of $1.89 per share which missed the analyst consensus estimate of $1.98 by 4.55 percent. This is a 25.59 percent decrease over earnings of…
benzinga.com Earnings Scheduled For April 30, 2026 - benzinga.com Citigroup Downgrades Bio-Rad Laboratories to Neutral, Lowers Price Target to $300 Citigroup analyst Patrick Donnelly downgrades Bio-Rad Laboratories (NYSE:BIO) from Buy to Neutral and lowers the price target from $375 to $300.
benzinga.com Pinterest Posts Downbeat Results, Joins DraftKings, Toast, Expedia And Other Big Stocks Moving Lower In Friday's Pre-Market Session 
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session - benzinga.com Bio-Rad Laboratories Sees FY2026 Sales $2.596B-$2.622B vs $2.630B Est Full-Year 2026 Financial OutlookBio-Rad is providing its financial outlook for the full-year 2026. The Company currently expects non-GAAP, currency neutral revenue growth of approximately 0.5 to 1.5…
benzinga.com Earnings Summary: Bio-Rad Laboratories Q4 
benzinga.com Bio-Rad Laboratories Q4 Adj. EPS $2.51 Misses $2.70 Estimate, Sales $693.200M Beat $688.758M Estimate Bio-Rad Laboratories (NYSE:BIO) reported quarterly earnings of $2.51 per share which missed the analyst consensus estimate of $2.70 by 7.04 percent. This is a 13.45 percent decrease over earnings of…- benzinga.com Earnings Scheduled For February 12, 2026
benzinga.com Qiagen Explores Possible Sale After New Buyer Talks: Report Qiagen is reviewing strategic options, including a potential sale, after renewed takeover interest from several buyers.- benzinga.com Citigroup Maintains Buy on Bio-Rad Laboratories, Raises Price Target to $375 Citigroup analyst Patrick Donnelly maintains Bio-Rad Laboratories (NYSE:BIO) with a Buy and raises the price target from $350 to $375.
- benzinga.com Wells Fargo Maintains Equal-Weight on Bio-Rad Laboratories, Raises Price Target to $340 Wells Fargo analyst Brandon Couillard maintains Bio-Rad Laboratories (NYSE:BIO) with a Equal-Weight and raises the price target from $265 to $340.
benzinga.com CORRECTION: Bio-Rad Laboratories Q3 Adj. EPS $2.26 Beats $1.93 Estimate, Sales $653.000M Beat $651.301M Estimate Bio-Rad Laboratories (NYSE:BIO) reported quarterly earnings of $2.26 per share which beat the analyst consensus estimate of $1.93 by 16.92 percent. This is a 11.88 percent increase over earnings of…- benzinga.com Bio-Rad Laboratories Affirms FY2025 Sales Guidance of $2.567B-$2.593B vs $2.593B Est Full-Year 2025 Financial OutlookBio-Rad is maintaining its financial outlook for the full year 2025. The company continues to expect non-GAAP, currency-neutral revenue growth of approximately 0 to…
benzinga.com Earnings Scheduled For October 29, 2025 
benzinga.com Bio-Rad Laboratories Analysts Raise Their Forecasts After Better-Than-Expected Q2 Earnings - benzinga.com RBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $409 RBC Capital analyst Conor McNamara maintains Bio-Rad Laboratories (NYSE:BIO) with a Outperform and raises the price target from $387 to $409.
benzinga.com Monolithic Power Systems, Workiva, Interface, AppFolio And Other Big Stocks Moving Higher On Friday 
benzinga.com Wells Fargo Maintains Equal-Weight on Bio-Rad Laboratories, Raises Price Target to $265 Wells Fargo analyst Brandon Couillard maintains Bio-Rad Laboratories (NYSE:BIO) with a Equal-Weight and raises the price target from $245 to $265.- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com Bio-Rad Laboratories Narrows FY2025 Sales Guidance from $2.541B-$2.606B to $2.567B-$2.593B vs $2.520B Est Bio-Rad Laboratories (NYSE:BIO) narrows FY2025 sales outlook from $2.541 billion-$2.606 billion to $2.567 billion-$2.593 billion vs $2.520 billion estimate.
- benzinga.com Bio-Rad Laboratories Q2 Adj. EPS $2.61 Beats $1.76 Estimate, Sales $651.600M Beat $615.110M Estimate Bio-Rad Laboratories (NYSE:BIO) reported quarterly earnings of $2.61 per share which beat the analyst consensus estimate of $1.76 by 48.63 percent. This is a 16.08 percent decrease over earnings of…
- benzinga.com Earnings Scheduled For July 31, 2025
- benzinga.com 5 Analysts Have This To Say About Bio-Rad Laboratories
- benzinga.com 10 Health Care Stocks With Whale Alerts In Today's Session